Studies: One Dose of "Psilocybin" from Magic Mushrooms Relieves Depression in 80% of Cancer Patients
New studies from NYU and John Hopkins University show the effectiveness of psilocybin in treating depression and anxiety of cancer patients.
The largest studies to date, by arguably the most respected institutions up to this point, show that psilocybin, a compound within "magic mushrooms", can be effective in treating depression and anxiety in cancer patients.
The studies were carried out on 29 patients by researchers at New York University (NYU) and on 51 patients at Johns Hopkins University.
Notably, up to 40% of all cancer patients are afflicted by psychological issues related to their illness.
Around 80% of the cancer patients in the studies got noticeably better after just one dose. And they sustained the psychological gains they made for up to seven months, with few minor side effects. Patients reported improvements in their quality of life, having more energy, going out more and having better relationships with family members.
Interestingly, those who had a stronger trip reported the strongest gains in alleviating their depression and anxiety.
A number of authorities in psychiatry and addiction medicine expressed their support for the work. These include Dr. Jeffrey Lieberman, a former president of the American Psychiatric Association and Dr. Daniel Shalev from the New York State Psychiatric Institute, who wrote that the studies are ”a model for revisiting criminalized compounds of interest in a safe, ethical way.”
The studies were also reviewed by regulators and were described by the New York Times as "most meticulous" to date.
The lead author of the Johns Hopkins study, psychiatrist Dr. Roland Griffiths, was optimistic on the possibilities of the new treatment, likening it to a groundbreaking surgery rather than the painstaking work to make feel people better used by traditional psychiatric approaches.
“I really don’t think we have any models in psychiatry that look like” the effects demonstrated in the two trials, said Griffiths. “Something occurs and it’s repaired and it’s better going forward … very plausibly for more than six months,” he added. “In that sense it’s a new model.”
One of the participants in the study, Sherry Marcy, described the changes in how she felt this way:
"The cloud of doom seemed to just lift… I got back in touch with my family and kids, and my wonder at life," said Marcy, whose been battling cancer from 2010. "Before, I was sitting alone at home, and I couldn't move … This study made a huge difference, and it's persisted."
Psilocybin-containing "magic mushrooms". Credit: Getty Images.
The particulars of both studies involved randomly offering patients either psilocybin or a placebo at the first session, and then giving them the opposite treatment seven weeks later. This way all participants eventually took psilocybin. In both studies, the success rate of psilocybin versus the placebo was very clear, with 83% getting better on psilocybin and only 14% on the placebo in the NYU study.
Psilocybin, of course, have been banned in the U.S. for over 40 years. While they were allowed to use it for their studies, the scientists warn against self-medicating depression by taking "magic mushrooms". They caution that professionals are needed to control the dosage and provide a supportive environment in which to experience the drug's effects. The psilocybin therapy may also not be appropriate for people with schizophrenia or young adults.
To move forward in this field, Dr. Shalev and Dr. Lieberman see a need to loosen research restrictions, because "there is much potential for new scientific insights and clinical applications.” Ideally, the next step would be a trial with a larger sample, perhaps across several centers with hundreds of subjects.
Not everyone is on board. Dr. William Breitbart, chairman of the psychiatry department at the Memorial Sloan-Kettering Cancer Center expressed his reservations about the use of cancer patients for the study.
“Medical marijuana got its foot in the door by making the appeal that ‘cancer patients are suffering, they’re near death, so for compassionate purposes, let’s make it available,’ ” he said. “And then you’re able to extend this drug to other purposes.”
The positive effect of psilocybin on depression was also demonstrated by studies earlier this year.
Cover photo credit: Langone Medical Center/New York University.
Delay, deny and deflect were the strategies Facebook has used to navigate scandals it's faced in recent years, according to the New York Times.
- The exhaustive report is based on interviews with more than 50 people with ties to the company.
- It outlines how senior executives misled the public and lawmakers in regards to what it had discovered about privacy breaches and Russian interference in U.S. politics.
- On Thursday, Facebook cut ties with one of the companies, Definers Public Relations, listed in the report.
Protected animals are feared to be headed for the black market.
Sure we know it would be bad, but what do all of these scary numbers really mean?
- At the press time, the value was $21.7 trillion dollars.
- Lots of people know that a default would be bad, but not everybody seems to get how horrible it would be.
- While the risk is low, knowing what would happen if a default did occur is important information for all voters.
SMARTER FASTER trademarks owned by The Big Think, Inc. All rights reserved.